Context Capital Management, LLC - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is and the CUSIP is 88339KAA0. A total of 23 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
Context Capital Management, LLC ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q2 2022$28,740,000
+16.3%
31,463
+22.3%
2.05%
+27.8%
Q1 2022$24,712,000
+2.1%
25,735
+2.6%
1.61%
-14.9%
Q4 2021$24,207,000
+2.8%
25,076
-1.2%
1.89%
-21.4%
Q3 2021$23,544,000
+24.6%
25,388
+28.0%
2.40%
+37.3%
Q2 2021$18,896,000
+96.0%
19,838
+109.4%
1.75%
+85.3%
Q1 2021$9,639,000
-24.4%
9,473
-99.9%
0.94%
-45.8%
Q4 2020$12,756,000
+101.0%
13,473,000
+85.8%
1.74%
+26.5%
Q3 2020$6,345,000
+276.6%
7,250,000
+314.3%
1.38%
+110.5%
Q2 2020$1,685,000
-50.3%
1,750,000
-50.0%
0.66%
-66.0%
Q1 2020$3,391,000
-56.9%
3,500,000
-53.3%
1.92%
-51.1%
Q4 2019$7,863,000
+41.3%
7,500,000
+25.0%
3.94%
+24.9%
Q3 2019$5,565,000
+7.9%
6,000,0000.0%3.15%
+5.4%
Q2 2019$5,158,000
-11.5%
6,000,0000.0%2.99%
-15.8%
Q1 2019$5,827,000
-13.1%
6,000,000
-7.7%
3.55%
-6.2%
Q4 2018$6,703,000
-13.0%
6,500,0000.0%3.79%
-15.5%
Q3 2018$7,702,000
+40.9%
6,500,000
+18.2%
4.48%
-4.7%
Q2 2018$5,466,000
+53.2%
5,500,000
+57.1%
4.70%
+81.5%
Q1 2018$3,567,000
-7.2%
3,500,0000.0%2.59%
+13.4%
Q4 2017$3,842,000
-10.4%
3,500,0000.0%2.28%
-20.4%
Q3 2017$4,288,000
-9.4%
3,500,0000.0%2.87%
-14.8%
Q2 2017$4,734,000
+48.9%
3,500,000
+40.0%
3.37%
+32.5%
Q1 2017$3,180,000
+83.8%
2,500,000
+66.7%
2.54%
+34.1%
Q4 2016$1,730,0001,500,0001.90%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q2 2021
NameSharesValueWeighting ↓
Context Capital Management, LLC 13,473,000$12,756,0001.74%
Shaolin Capital Management LLC 14,065,000$13,281,0000.93%
ZAZOVE ASSOCIATES LLC 3,773,000$3,584,0000.44%
FARALLON CAPITAL MANAGEMENT LLC 56,695,000$53,806,0000.32%
Baupost Group 30,000,000$28,396,0000.26%
Aequim Alternative Investments LP 3,000,000$2,840,0000.21%
WOLVERINE ASSET MANAGEMENT LLC 24,100,000$22,817,0000.17%
TENOR CAPITAL MANAGEMENT Co., L.P. 5,500,000$5,257,0000.15%
SSI INVESTMENT MANAGEMENT LLC 1,750,000$1,648,0000.12%
GABELLI & Co INVESTMENT ADVISERS, INC. 430,000$406,0000.06%
View complete list of THERAVANCE BIOPHARMA INC shareholders